Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Nomura, Takeo ^a   Yamasaki, Mutsushi ^a   Hirai, Kenichi ^a   Inoue, Toru ^a   Sato, Ryuta ^a   Matsuura, Keiko ^a   Moriyama, Masatsugu ^a   Sato, Fuminori ^a   Mimata, Hiromitsu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Androgen receptor; Chronic hypoxia; Docetaxel; Prostate cancer; Vav3

Indexed keywords

ANDROGEN RECEPTOR; ATELOCOLLAGEN; CASPASE 3; CASPASE 9; DNA; DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; SMALL INTERFERING RNA; SMALL INTERFERING RNA VAV3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; MOUSE; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-VAV; RECEPTORS, ANDROGEN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAXOIDS; TUMOR BURDEN;

MAMMALIA; MUS MUSCULUS;

EID: 84875861485     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-27     Document Type: Article

References (43)

1. Crawford ED, Eisenberg MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321:419-424. 10.1056/NEJM198908173210702, 2503724.
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004, 25:276-308. 10.1210/er.2002-0032, 15082523.
3. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004, 91:483-490. 10.1002/jcb.10653, 14755679.
4. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003, 89:552-556. 10.1038/sj.bjc.6601127, 2394367, 12888829.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1:34-45. 10.1038/35094009, 11900250.
6. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009, 15:3251-3255. 10.1158/1078-0432.CCR-08-1171, 19447877.
7. Hsu FN, Yang MS, Lin E, Tseng CF, Lin H. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells. Am J Physiol Endocrinol Metab 2011, 300:E902-E908. 10.1152/ajpendo.00610.2010, 21364123.
8. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008, 15:841-849. 10.1677/ERC-08-0084, 2740735, 18667687.
9. Raj GV, Barki-Harrington L, Kue PF, Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J Urol 2002, 167:1458-1463. 10.1016/S0022-5347(05)65345-1, 11832770.
10. Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Experimental oncogene induced prostate cancer. Cancer Surv 1991, 11:55-71.
11. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 1993, 90:8910-8914. 10.1073/pnas.90.19.8910, 47470, 8415631.
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8. 10.1056/NEJM199101033240101, 1701519.
13. Schröder F. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008, 53:1129-1137. 10.1016/j.eururo.2008.01.049, 18262723.
14. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop?. Urol Clin North Am 1999, 26:263-273. 10.1016/S0094-0143(05)70066-5, 10361549.
15. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol 2008, 22:597-608. 2262175, 18079321.
16. Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 2006, 20:1061-1072. 10.1210/me.2005-0346, 16384856.
17. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006, 20:2315-2325. 10.1210/me.2006-0048, 16762975.
18. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol 2000, 20:1461-1477. 10.1128/MCB.20.5.1461-1477.2000, 85310, 10669724.
19. Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene 2001, 20:6372-6381. 10.1038/sj.onc.1204780, 11607839.
20. Hornstein I, Alcover A, Katzav S. Vav proteins, masters of the world of cytoskeleton organization. Cell Signal 2004, 16:1-11. 10.1016/S0898-6568(03)00110-4, 14607270.
21. Zugaza JL, López-Lago MA, Caloca MJ, Dosil M, Movilla N, Bustelo XR. Structural determinants for the biological activity of Vav proteins. J Biol Chem 2002, 277:45377-45392. 10.1074/jbc.M208039200, 12228230.
22. Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989, 8:2283-2290. 401160, 2477241.
23. Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M, Welsh J, Wang LH. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 2000, 20:9212-9224. 10.1128/MCB.20.24.9212-9224.2000, 102179, 11094073.
24. Hirai K, Nomura T, Yamasaki M, Inoue T, Narimatsu T, Nakada C, Tsukamoto Y, Matsuura K, Sato F, Moriyama M, Mimata H. The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia. Urol Oncol 2013, in press.
25. Yamasaki M, Nomura T, Sato F, Mimata H. Chronic hypoxia induces androgen-independent and invasive behavior in LNCaP human prostate cancer cells. Urol Oncol 2012, in press.
26. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones A, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520. 10.1056/NEJMoa041318, 15470214.
27. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, . TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. 10.1056/NEJMoa040720, 15470213, TAX 327 Investigators.
28. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005, 6:229-239. 10.1016/S1470-2045(05)70094-2, 15811618.
29. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003, 9:2416-2425.
30. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001, 165:688-693. 10.1097/00005392-200102000-00095, 11176459.
31. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002, 277:29936-29944. 10.1074/jbc.M204733200, 12052835.
32. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Sotgia F. Understanding the " lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 2010, 10:537-542. 10.4161/cbt.10.6.13370, 3040943, 20861671.
33. Suzuki Y, Kondo Y, Hara S, Kimata R, Nishimura T. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions. Int J Urol 2010, 17:281-285. 10.1111/j.1442-2042.2010.02450.x, 20409220.
34. Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, Worthington J. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer 2008, 123:760-768. 10.1002/ijc.23418, 18512241.
35. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241. 10.1016/S0092-8674(00)80405-5, 9346240.
36. Scheid MP, Schubert KM, Duronio V. Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem 1999, 274:31108-31113. 10.1074/jbc.274.43.31108, 10521512.
37. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 2006, 103:14477-14482. 10.1073/pnas.0606836103, 1599986, 16973750.
38. Liu Y, Mo JQ, Hu Q, Boivin G, Levin L, Lu S, Yang D, Dong Z, Lu S. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res 2008, 68:6396-6406. 10.1158/0008-5472.CAN-08-0645, 2730641, 18676865.
39. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009, 9:237-249. 10.2174/156800909787580999, 2921605, 19275762.
40. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS. Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 2001, 276:23681-23688. 10.1074/jbc.M100279200, 11323415.
41. Bhakar AL, Howell JL, Paul CE, Salehi AH, Becker EB, Said F, Bonni A, Barker PA. Apoptosis induced by p75NTR overexpression requires Jun kinase-dependent phosphorylation of Bad. J Neurosci 2003, 23:11373-11381.
42. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 2005, 170:295-304. 10.1083/jcb.200409117, 2171419, 16009721.
43. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999, 19:8469-8478. 84954, 10567572.